 PLYMOUTH MEETING, Pa., June 10, 2021 PRNewswire -- Harmony Biosciences Holdings, Inc. Harmony Nasdaq: HRMY, a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced results of a new analysis evaluating number needed to treat NNT and effect sizes for treatment with WAKIX pitolisant that demonstrates the magnitude of its clinical effectiveness for excessive daytime sleepiness EDS and cataplexy in adults with narcolepsy. 